Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Relmada Therapeutics, Inc.

NASDAQ: RLMD · Life Sciences · 3 alerts · CIK 1553643

Share price
$3.61Close, Nov 16
Market cap
$385M
Shares outstanding
106.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Relmada Therapeutics, Inc. filings on SEC EDGAR ↗

4:11 PM ET 8-K
Financial Results

Relmada Therapeutics Financial Results

Relmada Therapeutics reported third quarter 2026 financial results and provided a corporate update on its NDV-01 and sepranolone programs. The company ended the quarter with $202.1 million in cash, which is expected to fund operations through 2029, and remains on track to submit an IND for NDV-01 by year-end 2026.

“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program.”

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics

“Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability. Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance.”

Bipin Dalmia, Chief Business Officer of Relmada Therapeutics
4:08 PM ET 10-Q
Financial Results

Relmada Therapeutics Q3 2026 Results: Net Loss of $13.9M, Loss Widens

Relmada Therapeutics reported a net loss of $45.8 million for the nine months ended September 30, 2026, compared to $37.5 million in the prior year, driven by increased research and development costs. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $202.1 million in cash and short-term investments.

Key figure
Net loss $13.9M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.